z-logo
open-access-imgOpen Access
CD33 ‐targeting extracellular vesicles deliver antisense oligonucleotides against FLT3‐ITD and miR ‐125b for specific treatment of acute myeloid leukaemia
Author(s) -
Chen Huan,
Jayasinghe Migara Kavishka,
Yeo Eric Yew Meng,
Wu Zhiyuan,
Pirisinu Marco,
Usman Waqas Muhammad,
Pham Thach Tuan,
Lim Kah Wai,
Tran Nhan Van,
Leung Anskar Y. H.,
Du Xin,
Zhang Qiaoxia,
Phan Anh Tuân,
Le Minh T. N.
Publication year - 2022
Publication title -
cell proliferation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.647
H-Index - 74
eISSN - 1365-2184
pISSN - 0960-7722
DOI - 10.1111/cpr.13255
Subject(s) - cd33 , oligonucleotide , myeloid leukaemia , in vivo , myeloid , cancer research , monoclonal antibody , medicine , immunology , chemistry , pharmacology , antibody , biology , stem cell , microbiology and biotechnology , gene , biochemistry , cd34
Acute Myeloid Leukaemia (AML) is the most common blood cancer in adults. Although 2 out of 3 AML patients go into total remission after chemotherapies and targeted therapies, the disease recurs in 60%–65% of younger adult patients within 3 years after diagnosis with a dramatically decreased survival rate. Therapeutic oligonucleotides are promising treatments under development for AML as they can be designed to silence oncogenes with high specificity and flexibility. However, there are not many well validated approaches for safely and efficiently delivering oligonucleotide drugs. This issue could be resolved by utilizing a new generation of delivery vehicles such as extracellular vesicles (EVs). Methods In this study, we harness red blood cell‐derived EVs (RBCEVs) and engineer them via exogenous drug loading and surface functionalization to develop an efficient drug delivery system for AML. Particularly, EVs are designed to target CD33, a common surface marker with elevated expression in AML cells via the conjugation of a CD33‐binding monoclonal antibody onto the EV surface. Results The conjugation of RBCEVs with the CD33‐binding antibody significantly increases the uptake of RBCEVs by CD33‐positive AML cells, but not by CD33‐negative cells. We also load CD33‐targeting RBCEVs with antisense oligonucleotides (ASOs) targeting FLT3‐ITD or miR‐125b, 2 common oncogenes in AML, and demonstrate that the engineered EVs improve leukaemia suppression in in vitro and in vivo models of AML. Conclusion Targeted RBCEVs represent an innovative, efficient, and versatile delivery platform for therapeutic ASOs and can expedite the clinical translation of oligonucleotide drugs for AML treatments by overcoming current obstacles in oligonucleotide delivery.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here